Best Hospitals for Blood Cancer Treatment in Dubai, UAE

The cost of blood cancer treatment varies significantly based on the type of cancer (leukemia, lymphoma, or multiple myeloma), the treatment protocol required, and whether hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy is involved. In India, at JCI- or NABH-accredited cancer centers, the total cost for a comprehensive treatment course — including chemotherapy induction cycles, diagnostics (NGS, PET-CT, bone marrow studies), and autologous or allogeneic stem cell transplantation — typically ranges from USD 7,000 to USD 55,000. A single chemotherapy induction course (e.g., 7+3 for AML or R-CHOP for DLBCL) ranges from USD 7,000–15,000, while allogeneic HSCT from a matched unrelated donor (MUD) ranges from USD 30,000–55,000. In the UAE, at JCI-accredited and DHA-licensed oncology centers in Dubai and Abu Dhabi, equivalent treatment costs range from USD 18,000 to USD 120,000, with allogeneic HSCT in the range of USD 70,000–120,000. India is typically 40–60% less expensive than the UAE for equivalent oncology protocols using the same WHO-approved drug regimens and international-standard diagnostics. GAF Healthcare provides fully transparent, itemized cost estimates inclusive of hospital stay, chemotherapy drugs, supportive medications, and monitoring investigations before any commitment is made.

The required in-country stay before international air travel is medically safe is highly dependent on the treatment modality. For patients receiving outpatient or short-stay chemotherapy cycles (e.g., CML patients on oral TKI therapy, or patients completing a single R-CHOP cycle for lymphoma), a minimum in-country stay of 3–4 weeks per cycle is recommended to allow for CBC recovery assessment, response evaluation, and management of any immediate toxicity. For patients undergoing autologous HSCT (common for multiple myeloma and relapsed Hodgkin/NHL), the minimum safe in-country stay is 6–8 weeks from the date of stem cell reinfusion (Day 0), once ANC engraftment is confirmed, no active infections are present, and the patient can independently manage oral medications. For patients undergoing allogeneic HSCT (matched sibling, MUD, or haploidentical donor transplant), international air travel is not medically cleared until a minimum of 90 days post-transplant, as this window is critical for GvHD surveillance, chimerism monitoring, immune reconstitution assessment, and infectious complication management. Patients who develop acute GvHD, viral reactivation (CMV, EBV), or delayed engraftment may require an extended stay of 4–5 months. GAF Healthcare works closely with the transplant physician team to provide patients with a formal fit-to-fly certificate, coordinate extended visa arrangements as needed, and arrange continuity of care documentation for the patient's home oncologist.

Success rates in blood cancer treatment vary considerably by diagnosis, disease stage, patient age, and molecular risk stratification, and the figures reported at JCI-accredited centers in India and the UAE are consistent with international benchmarks published by the NMDP, EBMT, and SEER. For Acute Lymphoblastic Leukemia (ALL) in children, complete remission rates exceed 95% with modern multi-agent protocols (BFM or COG-based), with 5-year event-free survival of approximately 85–90%. For adult ALL, 5-year overall survival ranges from 40–60%, improving significantly in BCR-ABL1-positive ALL with the addition of TKI therapy and CAR-T in the relapsed setting. For Acute Myeloid Leukemia (AML), induction remission is achieved in 60–80% of younger patients; 5-year overall survival with allogeneic HSCT in favorable-risk AML approaches 60–70%. For Diffuse Large B-Cell Lymphoma (DLBCL), first-line R-CHOP produces a 5-year overall survival of approximately 60–70%; patients achieving complete metabolic response (PET-negative) at end-of-treatment have outcomes exceeding 75%. For Hodgkin Lymphoma (early-stage), cure rates with ABVD or BV-AVD exceed 85–90%. For Multiple Myeloma, while not considered curable with current standard therapy, modern quadruplet induction followed by autologous HSCT and lenalidomide maintenance achieves a median progression-free survival of 5–7 years in transplant-eligible patients, with some patients achieving 10+ year remissions. For CML, treatment with second-generation TKIs achieves major molecular response (MMR) in over 80% of patients at 12 months, with near-normal life expectancy in optimal responders. GAF Healthcare facilitates treatment at high-volume centers where these outcomes are consistently achieved and where multidisciplinary tumor boards, molecular diagnostics, and advanced cellular therapy capabilities are all available under one roof.